JP2023540081A - キノリンｃｇａｓアンタゴニスト化合物 - Google Patents

キノリンｃｇａｓアンタゴニスト化合物 Download PDF

Info

Publication number
JP2023540081A
JP2023540081A JP2023513934A JP2023513934A JP2023540081A JP 2023540081 A JP2023540081 A JP 2023540081A JP 2023513934 A JP2023513934 A JP 2023513934A JP 2023513934 A JP2023513934 A JP 2023513934A JP 2023540081 A JP2023540081 A JP 2023540081A
Authority
JP
Japan
Prior art keywords
alkyl
teeth
compound according
ring
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023513934A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023540081A5 (https=
Inventor
チウ、ジエン
ウェイ、チー
チャンツ、マット
シー、へピン
ウー、ユートン
タン、フイリン
サン、リジュン
チェン、チュオ
チェン、ジージエン
Original Assignee
イミューンセンサー セラピューティクス、インコーポレイテッド
ザ ボード オブ リージェンツ オブ ザ ユニバーシティ オブ テキサス システム
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イミューンセンサー セラピューティクス、インコーポレイテッド, ザ ボード オブ リージェンツ オブ ザ ユニバーシティ オブ テキサス システム filed Critical イミューンセンサー セラピューティクス、インコーポレイテッド
Publication of JP2023540081A publication Critical patent/JP2023540081A/ja
Publication of JP2023540081A5 publication Critical patent/JP2023540081A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C07D215/46—Nitrogen atoms attached in position 4 with hydrocarbon radicals, substituted by nitrogen atoms, attached to said nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6503—Five-membered rings
    • C07F9/65031—Five-membered rings having the nitrogen atoms in the positions 1 and 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6503—Five-membered rings
    • C07F9/6506—Five-membered rings having the nitrogen atoms in positions 1 and 3

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2023513934A 2020-09-03 2021-09-03 キノリンｃｇａｓアンタゴニスト化合物 Pending JP2023540081A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063074446P 2020-09-03 2020-09-03
US63/074,446 2020-09-03
US202063124713P 2020-12-11 2020-12-11
US63/124,713 2020-12-11
US202163196146P 2021-06-02 2021-06-02
US63/196,146 2021-06-02
PCT/US2021/049084 WO2022051634A1 (en) 2020-09-03 2021-09-03 Quinoline cgas antagonist compounds

Publications (2)

Publication Number Publication Date
JP2023540081A true JP2023540081A (ja) 2023-09-21
JP2023540081A5 JP2023540081A5 (https=) 2024-09-10

Family

ID=78086041

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023513934A Pending JP2023540081A (ja) 2020-09-03 2021-09-03 キノリンｃｇａｓアンタゴニスト化合物

Country Status (13)

Country Link
US (3) US11873291B2 (https=)
EP (1) EP4208452A1 (https=)
JP (1) JP2023540081A (https=)
KR (1) KR20230062845A (https=)
CN (1) CN116234802A (https=)
AU (1) AU2021336977A1 (https=)
BR (1) BR112023003948A2 (https=)
CA (1) CA3191172A1 (https=)
IL (1) IL300976A (https=)
MX (1) MX2023002553A (https=)
TW (1) TW202227407A (https=)
WO (1) WO2022051634A1 (https=)
ZA (1) ZA202304064B (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021209473A1 (en) * 2020-04-16 2021-10-21 F. Hoffmann-La Roche Ag Biphenyl derivatives
KR20230062845A (ko) 2020-09-03 2023-05-09 이뮨센서 테라퓨틱스, 인코포레이티드 퀴놀린 cgas 길항제 화합물
WO2022137085A1 (en) 2020-12-22 2022-06-30 Novartis Ag Indole derivatives useful in treating conditions associated with cgas
IL315346A (en) 2022-03-02 2024-11-01 Immunesensor Therapeutics Inc CGAS agonistic quinoline compounds
CN118265696A (zh) * 2022-11-07 2024-06-28 深圳博瑞医药科技有限公司 一种芳基羧酸类化合物及其制备Mrgpr X4抑制剂的用途
WO2024099135A1 (zh) * 2022-11-11 2024-05-16 杭州中美华东制药有限公司 1,5-萘啶类cGAS抑制剂及其用途
AU2024326748A1 (en) 2023-08-18 2026-04-02 Katholieke Universiteit Leuven 1,3-dihydro-2h-pyrrolo[3,4-c]quinoline derivatives as cgas inhibitors for the treatment of inflammatory and/or autoimmune diseases
GB202314609D0 (en) * 2023-09-22 2023-11-08 Univ College Cardiff Consultants Ltd Iminosugar prodrug compounds
WO2025147600A1 (en) * 2024-01-05 2025-07-10 Dewpoint Therapeutics, Inc. Amino quinoline compounds and uses thereof
WO2026057087A1 (zh) * 2024-09-14 2026-03-19 杭州英创医药科技有限公司 作为cGAS抑制剂的化合物

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010532352A (ja) * 2007-06-29 2010-10-07 ギリアード サイエンシーズ， インコーポレイテッド 抗ウイルス化合物
CN109111426A (zh) * 2017-06-23 2019-01-01 中国科学院上海药物研究所 一类稠合双环杂芳基或芳基化合物，及其用途
WO2019051269A1 (en) * 2017-09-08 2019-03-14 The Board Of Trustees Of The Leland Stanford Junior University ENPP1 INHIBITORS AND THEIR USE FOR THE TREATMENT OF CANCER
WO2019241787A1 (en) * 2018-06-15 2019-12-19 The Regents Of The University Of Colorado A Body Corporate Novel cyclic gmp-amp synthase (cgas) inhibitors and their method of use
WO2020023846A1 (en) * 2018-07-27 2020-01-30 Arcus Biosciences, Inc. Pyridone a2r antagonists
WO2020142735A1 (en) * 2019-01-04 2020-07-09 BellBrook Labs Inhibitors of cgas activity as therapeutic agents

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3542785A (en) 1967-05-15 1970-11-24 Ciba Geigy Corp 2-hydroxy-4-aryl-quinolines
US3668207A (en) 1970-01-22 1972-06-06 Ciba Geigy Corp 2-amino-4-aryl-quinolines
BR0312204A (pt) 2002-06-27 2005-04-26 Schering Ag Antagonista de receptor ccr5 de quinolina substituìda
CA2699697A1 (en) 2007-09-27 2009-04-02 F. Hoffmann-La Roche Ag Quinoline derivatives as 5ht5a receptor antagonists
US20190127354A1 (en) 2015-12-14 2019-05-02 Fundación Para La Investigación Médica Aplicada 2,4,6,7-tetrasubstituted quinoline compounds as inhibitors of dna methyltransferases
EP3620164A1 (en) 2018-09-05 2020-03-11 Genoscience Pharma SAS Substituted 2,4 diamino-quinoline as new medicament for fibrosis, autophagy and cathepsins b (ctsb), l (ctsl) and d (ctsd) related diseases
US11245538B2 (en) * 2019-09-28 2022-02-08 Intel Corporation Methods and apparatus to aggregate telemetry data in an edge environment
AU2021211437A1 (en) 2020-01-20 2022-09-15 Crescenta Biosciences Novel cell metabolism modulating compounds and uses thereof
WO2022010948A1 (en) 2020-07-06 2022-01-13 Crescenta Biosciences Novel cell metabolism modulating compounds and uses thereof for the treatment of viral diseases
KR20230062845A (ko) 2020-09-03 2023-05-09 이뮨센서 테라퓨틱스, 인코포레이티드 퀴놀린 cgas 길항제 화합물
IL315346A (en) 2022-03-02 2024-11-01 Immunesensor Therapeutics Inc CGAS agonistic quinoline compounds

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010532352A (ja) * 2007-06-29 2010-10-07 ギリアード サイエンシーズ， インコーポレイテッド 抗ウイルス化合物
CN109111426A (zh) * 2017-06-23 2019-01-01 中国科学院上海药物研究所 一类稠合双环杂芳基或芳基化合物，及其用途
WO2019051269A1 (en) * 2017-09-08 2019-03-14 The Board Of Trustees Of The Leland Stanford Junior University ENPP1 INHIBITORS AND THEIR USE FOR THE TREATMENT OF CANCER
WO2019241787A1 (en) * 2018-06-15 2019-12-19 The Regents Of The University Of Colorado A Body Corporate Novel cyclic gmp-amp synthase (cgas) inhibitors and their method of use
WO2020023846A1 (en) * 2018-07-27 2020-01-30 Arcus Biosciences, Inc. Pyridone a2r antagonists
WO2020142735A1 (en) * 2019-01-04 2020-07-09 BellBrook Labs Inhibitors of cgas activity as therapeutic agents

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
"CAS REGISTRY No. 2442651-45-6他", DATABASE REGISTRY [ONLINE], vol. [検索日2025.06.22], JPN7025003052, 2020, pages Retrieved from: STN, ISSN: 0005637123 *
BERING, L. ET AL.: ""Regioselective Metal-Free Cross-Coupling of Quinoline N-Oxides with Boronic Acids"", ORGANIC LETTERS, vol. 17, no. 12, JPN6025027990, 2015, pages 3134 - 3137, ISSN: 0005637124 *
FALDU, V. J. ET AL.: ""Synthesis, Characterization and Biological Evaluation of some Newer 5-[6-Chloro/Fluor/Nitro-2-(p-C", INTERNATIONAL LETTERS OF CHEMISTRY, PHYSICS AND ASTRONOMY, vol. 25, JPN6025027993, 2014, pages 26 - 32, ISSN: 0005637127 *
OSAMA, L. ET AL.: ""Synthesis and molecular modeling of new quinoline derivatives as antitumor agents"", DER PHARMA CHEMICA, vol. 2016年, Vol. 8, No. 14, JPN6025027992, pages 100 - 110, ISSN: 0005637126 *
VERBANAC, D. ET AL.: ""Synthesis and evaluation of antibacterial and antioxidant activity of novel 2-phenyl-quinoline ana", JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY, vol. 31, no. 2, JPN6025027991, 2016, pages 104 - 110, ISSN: 0005637125 *
YU, X. Y. ET AL.: ""A series of quinoline analogues as potent inhibitors of C. albicans prolyl tRNA synthetase"", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 11, no. 4, JPN6025027994, 2001, pages 541 - 544, ISSN: 0005637128 *

Also Published As

Publication number Publication date
CA3191172A1 (en) 2022-03-10
ZA202304064B (en) 2024-09-25
US20240092760A1 (en) 2024-03-21
US11873291B2 (en) 2024-01-16
KR20230062845A (ko) 2023-05-09
EP4208452A1 (en) 2023-07-12
TW202227407A (zh) 2022-07-16
BR112023003948A2 (pt) 2023-04-11
WO2022051634A1 (en) 2022-03-10
MX2023002553A (es) 2023-05-09
US20230081291A1 (en) 2023-03-16
AU2021336977A1 (en) 2023-03-23
US20250115579A1 (en) 2025-04-10
IL300976A (en) 2023-04-01
US12134609B2 (en) 2024-11-05
CN116234802A (zh) 2023-06-06

Similar Documents

Publication Publication Date Title
JP2023540081A (ja) キノリンｃｇａｓアンタゴニスト化合物
US10780090B2 (en) Heteroaryl compounds useful as inhibitors of SUMO activating enzyme
AU2013334236B2 (en) Heteroaryl inhibitors of PDE4
JP2024540080A (ja) Ｉｒａｋ４分解剤およびその合成
CN106029076A (zh) 作为bet溴域抑制剂的苯并哌嗪组合物
AU2022214618A1 (en) Cdk2 inhibitors and methods of using the same
EP4423068B1 (en) Rxfp1 agonists
EP4472946A1 (en) Fused bicyclic heterocyclyl compounds as usp1 inhibitors
JP2025507820A (ja) キノリンｃＧａｓアンタゴニスト化合物
TW201734020A (zh) 布魯頓氏酪胺酸激酶抑制劑及其使用方法
JP2025507820A5 (https=)
CN117396474A (zh) 血浆激肽释放酶抑制剂
TW202515851A (zh) Keap1抑制劑及其用途
CN114599651A (zh) 作为造血祖细胞激酶1(hpk1)抑制剂的吲唑类药物及其使用方法
HK40094674A (zh) 喹啉cgas拮抗剂化合物
HK40120448A (zh) 喹啉cgas拮抗剂化合物
CA3109195A1 (en) Transglutaminase 2 (tg2) inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240902

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240902

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250708

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250710

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251008

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260107

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260303